RootPath

RootPath is a Cambridge-based biotechnology company developing a powerful personalized T-cell therapy platform that bridges precision medicine and cancer immunotherapy. Our next-generation technology enables us to precisely monitor, modulate, and guide the immune system to revolutionize cancer diagnosis and treatment. RootPath was incubated in 2017 by Nest.Bio Ventures and is composed of scientists from top institutions such as Harvard University and MIT, with leading-edge capabilities in synthetic biology and cell therapy technology development via its world-class gene synthesis platform. This platform holds tremendous potential value across various fields, including TIL, TCR-T, CAR-T, CAR-NK cell therapies, large-molecule drugs, and gene therapy.